NuCana plc (NCNA) Form 6-K — Sep 30, 2026

$NCNAForm 6-KFiled Sep 30, 2026, 8:09 AM ET0001193125-26-408365Original filing

NuCana plc announced on September 30, 2026 that the European Patent Office granted patent EP 3683225 covering the composition of matter of NUC-7738, its novel anti-cancer agent. NUC-7738 is now protected by over 85 issued patents worldwide, with similar composition-of-matter patents already granted in the US and China. The drug is in the Phase 2 portion of a Phase 1/2 study combined with Keytruda in PD-1 inhibitor-resistant metastatic melanoma.

Key figures

Cash runway: funded into 2029
Patent number: EP 3683225
Issued patents worldwide: over 85

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.